The Impact of Gene Polymorphisms on the Success of Anticholinergic Treatment in Children with Overactive Bladder

Table 1

The gene-specific primer sequences, PCR products, and restriction endonucleases (REs).

Polymorphisms	Primers	PCR products (bp)	REs	Alleles (bp)
ARHGEF10 (rs4376531); C>G	F: 5′CACCACTAAACATGCCCTAT3′; R: 5′TAACAACGAAAAGTAGTAGC3′	369	PsuI	C allele: 369; G allele: 153, 216
ROCK2 (rs2230774); A>C	F: 5′AGTGACTCTCCATCTTGTAGAGAAG3′; R: 5′AGCCATGTAGAAGTCCTCTTTG3′	274	MboII	A allele: 274; C allele: 34, 240
ADRB3 (rs4994); T>C	F: 5′CCAGTGGGCTGCCAGGGG3′; R: 5′GCCAGTGGCGCCCAACGG3′	248	MvaI	T allele: 97, 62, 61, 15, 13; C allele: 158, 62, 15,13
CYP3A4 (rs2740574); A>G	F: 5′GGAATGAGGACAGCCATAGAGACA AGGGGA3′; R: 5′CCTTTCAGCTCTGTGTTGCTCTTTGCTG3′	385	MboII	A allele: 175, 169, 41; G allele: 210, 175